8-KLeadership ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Executive Changes (Oct 22, 2014)

Filed October 22, 2014For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) announced a change to its Board of Directors on October 17, 2014, with this announcement filed on October 22, 2014. The Board's size was increased from 10 to 11 directors, and a new independent director, Dr. Jeffrey M. Leiden, was elected. Dr. Leiden, who is also the Chairman, President, and CEO of Vertex Pharmaceuticals, will begin his term on December 1, 2014. This addition to the board is significant as Dr. Leiden brings executive leadership experience from the biopharmaceutical industry. His appointment to the Compensation Committee suggests a focus on executive compensation strategy and oversight. Investors can view this as a move to strengthen board expertise and governance, potentially bringing fresh perspectives to the company's strategic direction and executive remuneration policies.

Key Highlights

  • 1Board size increased from 10 to 11 directors.
  • 2Jeffrey M. Leiden, M.D., Ph.D., elected as a new independent director, effective December 1, 2014.
  • 3Dr. Leiden is Chairman, President, and CEO of Vertex Pharmaceuticals.
  • 4Dr. Leiden has been appointed to the Board's Compensation Committee.
  • 5The company has confirmed Dr. Leiden meets independence standards set by NYSE and company guidelines.
  • 6Dr. Leiden will receive standard non-employee director compensation, including a one-time restricted share unit grant valued at $77,790.

Frequently Asked Questions

Dr. Jeffrey M. Leiden is the Chairman, President, and CEO of Vertex Pharmaceuticals. He was elected to the Quest Diagnostics Board of Directors to fill a newly created position. His appointment is effective December 1, 2014, and he is considered an independent director.

Dr. Leiden's appointment to the Compensation Committee suggests a focus on executive compensation. This role involves overseeing and making recommendations on the compensation of the company's top executives, indicating a potential emphasis on aligning executive pay with company performance and shareholder interests.

Dr. Leiden will receive compensation in line with the company's standard practices for non-employee directors. This includes a one-time grant of restricted share units valued at $77,790 upon joining the board.

The increase in the Board's size and the election of Dr. Leiden are effective December 1, 2014.